Taxonomy Code 1835X0200X(1835x0200x)
Oncology Pharmacist. Providers: 15
Oncology Pharmacist Providers
| NPI | Name | Type | Address |
|---|---|---|---|
|
MR. PHARM.D. Rakesh Beri |
Individual |
833 S Wood St Chicago, IL |
|
|
DR. PHARMD Sandra Cuellar Puri |
Individual |
833 S Wood St # 886 Suite 164 Chicago, IL |
|
|
PHARM D Michael Pacini |
Individual |
1740 W Taylor St Chicago, IL |
|
|
PHARMD Richard Anzalone |
Individual |
1801 W. Taylor Street Uic Oncology Pharmacy Room 1411 Chicago, IL |
|
|
DR. PHARM.D. Latha Radhakrishnan |
Individual |
833 S Wood Room 164 University Of Illinois, College Of Pharmacy Mc 886 Chicago, IL |
|
|
DR. PHARMD Jamie Frances Sovcik |
Individual |
2300 N Children's Plaza Box 74 Chicago, IL |
|
|
PHARM.D., BCOP Barbara Yim |
Individual |
1901 W Harrison St # Ll170 Department Of Pharmacy Chicago, IL |
|
|
Chunchu Hsu |
Individual |
5145 N California Ave Chicago, IL |
|
|
DR. PHARMD Ashley Danielle Hicks |
Individual |
250 E Superior St 15 Prentice Pharmacy Chicago, IL |
|
|
DR. PHARMD Patrick Joseph Fleming JR. |
Individual |
1801 W Taylor St Chicago, IL |
|
|
RPH, BCPS Laura Shandonay |
Individual |
2900 N Lake Shore Dr Chicago, IL |
|
|
DR. PHARM.D. Christopher James Campbell |
Individual |
233 E Superior St Chicago, IL |
|
|
PHARMD Trevor Nelson Christ |
Individual |
1725 W Harrison St Ste 1059 Chicago, IL |
|
|
PHARMD Peter Wu |
Individual |
1725 W Harrison St Chicago, IL |
|
|
PHARMD Talha Shahid Khan |
Individual |
251 E Huron St Chicago, IL |
How to obtain, renew, or terminate an NPI
Every health care provider, whether it’s a hospital, pharmacy, or individual specialist, must obtain their own NPI number. This identification number is unique and is assigned upon application. In tod...
| Taxonomy Code | 1835X0200X |
| Specialization | Oncology |
| Display Name | Oncology Pharmacist |
| Taxonomy Group | Pharmacy Service Providers |
| Taxonomy Classification | Pharmacist |
| Definition | A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases. |
| Effective Date | September 30, 2009 |